Stocktoria
Korro Bio, Inc. KRRO
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2019-10-03
Chart by TradingView
2/9
Piotroski F — financial health
-13.3
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $6.4M | $2.3M | $0 | $0 | $14.1M |
| Operating income | -$121.9M | -$91.9M | -$84.5M | -$59.0M | -$84.0M |
| Net income | -$117.3M | -$83.6M | -$81.2M | -$58.0M | -$84.7M |
| Operating cash flow | -$78.6M | -$60.1M | -$67.3M | -$53.6M | -$76.1M |
| Free cash flow | -$79.1M | -$78.0M | -$75.1M | -$58.8M | -$79.0M |
| Total assets | $113.5M | $226.2M | $221.7M | $73.7M | $185.4M |
| Total liabilities | $62.1M | $65.8M | $51.8M | $8.9M | $54.5M |
| Shareholders' equity | $51.4M | $160.4M | $169.9M | -$99.0M | -$42.2M |
| Ratios | |||||
| Operating margin | -1906.4% | -4047.1% | — | — | -597.3% |
| Net margin | -1834.5% | -3680.4% | — | — | -602.0% |
| FCF margin | -1237.2% | -3433.6% | — | — | -561.4% |
| Return on assets | -103.3% | -36.9% | -36.6% | -78.7% | -45.7% |
| Return on equity | -228.0% | -52.1% | -47.8% | 58.6% | 200.6% |
| Current ratio | 6.90 | 8.79 | 8.87 | 6.56 | 11.79 |
| Revenue growth | 181.5% | — | — | -100.0% | -62.0% |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | 136,227 | $1.5M |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -13.3 (distress)
- Working capital / assets 0.621
- Retained earnings / assets -3.382
- EBIT / assets -1.074
- Equity / liabilities 0.829
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001703647 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.